



Antibody Drug Conjugates:

*Technologies and Global
Markets*

June 2017

Shalini S.Dewan

Report Code: PHM161B

Table of Contents

| | |
|---|-----------|
| Chapter 1: Introduction | 1 |
| Study Goals and Objectives..... | 1 |
| Reasons for Doing This Study..... | 1 |
| Scope of Report..... | 1 |
| Information Sources..... | 2 |
| Methodology..... | 2 |
| Geographic Breakdown..... | 2 |
| Analyst's Credentials..... | 6 |
| Related BCC Research Reports..... | 6 |
| Chapter 2: Summary and Highlights | 8 |
| Chapter 3: Market and Technology Background | 12 |
| Definitions..... | 12 |
| Components of ADCs | 13 |
| How ADCs Work..... | 13 |
| Historical Perspective..... | 13 |
| Advantages of ADCs..... | 15 |
| Approved ADCs | 15 |
| Mylotarg (Gemtuzumab Ozogamicin) | 15 |
| Adcetris (Brentuximab Vedotin)..... | 16 |
| Kadcyla (Trastuzumab-DM1)..... | 17 |
| Antibody Drug Conjugation Technologies | 17 |
| Key ADC Targets..... | 18 |
| CD19 | 19 |
| CD20 | 19 |
| CD22 | 19 |
| CD25 | 19 |
| CD30..... | 20 |
| CD33..... | 20 |
| CD40..... | 20 |
| CD56..... | 20 |
| CD74..... | 21 |
| CD79a and CD79b..... | 21 |
| CD138 (Syndecan-1)..... | 21 |
| CEACAM (Carcinoembryonic Antigen-Related Cell Adhesion Molecule)..... | 22 |
| EGFR (Epidermal Growth Factor Receptor/ERBB1)..... | 22 |
| EGP-1 (Epithelial Glycoprotein-1 Antigen) | 22 |
| GPNMB..... | 23 |
| HER2 (Human Epidermal Growth Factor Receptor)..... | 23 |
| LIV-1..... | 23 |
| Mesothelin | 23 |
| Nectin-4 | 24 |
| Prostate-Specific Membrane Antigen (PSMA) | 24 |
| SLITRK6 | 24 |
| VEGF (Vascular Endothelial Growth Factor)..... | 24 |
| Types of Monoclonal Antibodies | 25 |

| | |
|--|-----------|
| Types of Payloads (Cytotoxic Agents) | 26 |
| Types of Linkers..... | 27 |
| Conjugation Methods | 28 |
| Conventional Conjugation Method | 28 |
| Site-Specific Conjugation..... | 29 |
| Chapter 4: Market Breakdown by Technology Type | 32 |
| Market for ADCs by Type of Payload | 35 |
| Market Overview..... | 36 |
| Market Revenues | 37 |
| Market for ADCs by Type of Monoclonal Antibody | 38 |
| Market Overview..... | 39 |
| Market Revenues | 40 |
| Market for ADCs by Type of Linker | 42 |
| Market Overview..... | 42 |
| Market Revenues | 44 |
| Chapter 5: Market Breakdown by Application | 47 |
| Global Market for the Application of ADCs in Treating Various Types of Cancers | 47 |
| Market Share..... | 49 |
| Breast Cancer | 50 |
| Lymphoma..... | 54 |
| Other Types of Cancer | 57 |
| Chapter 6: Industry Structure | 62 |
| Market Leaders | 63 |
| Market Share | 63 |
| Chapter 7: Market Breakdown by Region | 66 |
| Market Overview | 67 |
| Market Revenues | 68 |
| Market for ADCs by Target Antigen | 69 |
| Market for CD-30 Targeting ADCs | 70 |
| Market for HER2 Targeting ADCs | 74 |
| Market for Other Antigen Targeting ADCs..... | 78 |
| Chapter 8: Patent Review/New Developments | 83 |
| Patent Analysis..... | 83 |
| Patents by Year..... | 83 |
| Patents by Company..... | 84 |
| Patents by Country | 86 |
| Patents by Assignee..... | 88 |
| New Developments..... | 88 |
| CMC-544..... | 89 |
| CDX-011 | 89 |
| RG7596 (Polatuzumab Vedotin)..... | 90 |
| RG7593 (Pinatuzumab Vedotin)..... | 90 |
| PSMA ADC | 90 |
| IMGN853 (Mirvetuximab Soravtansine) | 90 |
| BT-062 | 91 |
| Regulatory Issues | 96 |
| Regulatory History of Approved ADCs | 97 |

| | |
|--|------------|
| Regulatory Exclusivity..... | 98 |
| Other Regulatory Issues | 98 |
| Chapter 9: Analysis of Market Opportunities | 101 |
| Key Drivers | 101 |
| Patent Expiration..... | 101 |
| Targeted Nature of ADCs..... | 101 |
| Complexity of ADCs | 102 |
| Investor Confidence in Biologics | 102 |
| Increased Research on ADC Development..... | 102 |
| Other Factors..... | 102 |
| Key Challenges | 103 |
| Manufacturer Strategies..... | 103 |
| Chapter 10: Company Profiles | 107 |
| Appendix: Abbreviations..... | 135 |
| About BCC Research..... | 137 |
| About BCC Research..... | 138 |
| BCC Membership | 138 |
| BCC Custom Research | 138 |

List of Tables

| | |
|---|-----|
| Summary Table: Global Market for Antibody Drug Conjugates, by Region, Through 2021 (\$ Millions) | 10 |
| Table 1 History of Antibody Drug..... | 14 |
| Table 2 Types of Antibody Drug Conjugates Based on Type of Monoclonal Antibody | 25 |
| Table 3 Significant Antibody Drug Conjugate Payloads | 27 |
| Table 4 Significant Antibody Drug Conjugate Linkers | 28 |
| Table 5 Commercially Available Antibody Drug Conjugates: Key Components and Target Antigens | 33 |
| Table 6 Antibody Drug Conjugates with Significant Market Potential During the Forecast Period | 35 |
| Table 7 Global Market for Antibody Drug Conjugates, by Type of Payload, Through 2021 (\$ Millions) | 37 |
| Table 8 Global Market for Antibody Drug Conjugates, by Type of mAb, Through 2021 (\$ Millions) | 41 |
| Table 9 Global Market for Antibody Drug Conjugates, by Type of Linker, Through 2021 (\$ Millions) | 44 |
| Table 10 Global Market for Antibody Drug Conjugates, by Type of Cancer, Through 2021 (\$ Millions) ... | 48 |
| Table 11 Global Market Shares of Antibody Drug Conjugates, by Type of Cancer, 2016 (%) | 49 |
| Table 12 Global Market for Breast Cancer Antibody Drug Conjugates, by Region, Through 2021 (\$ Millions) | 53 |
| Table 13 Global Market for Lymphoma Antibody Drug Conjugates, by Region, Through 2021 (\$ Millions) | 57 |
| Table 14 Global Market for Other Types of Antibody Drug Conjugates, by Region, Through 2021 (\$ Millions) | 60 |
| Table 15 Leading Manufacturers/Suppliers of Antibody Drug Conjugates, 2016 | 63 |
| Table 16 Global Market Shares of Manufacturers/Suppliers for Antibody Drug Conjugates, 2016 (%) | 63 |
| Table 17 Global Market for Antibody Drug Conjugates, by Region, Through 2021 (\$ Millions) | 68 |
| Table 18 Significant Early Stage Clinical Trials on Adcetris, 2017 | 72 |
| Table 19 Global Market for CD30 Targeting Antibody Drug Conjugates, by Region, Through 2021 (\$ Millions) | 73 |
| Table 20 Significant Early Stage Clinical Trials on Kadcyla, 2017 | 76 |
| Table 21 Global Market for HER2 Targeting Antibody Drug Conjugates, by Region, Through 2021 (\$ Millions) | 77 |
| Table 22 Global Market for Other Types of Targeting Antibody Drug Conjugates, by Region, Through 2021 (\$ Millions) | 81 |
| Table 23 Number of U.S. Patents on ADCs Issued by Year, 2013 Through Feb. 2017 | 84 |
| Table 24 Number of U.S. Patents on ADCs Held by Company, 2013 Through Feb. 2017..... | 85 |
| Table 25 Number of U.S. Patents on ADCs by Assignee’s Country, 2013 Through Feb. 2017..... | 86 |
| Table 26 U.S. Patent Shares of ADCs by Assignee’s Country, 2013 Through Feb. 2017 (No./%) | 87 |
| Table 27 Number of U.S. Patents on ADCs by Type of Assignee, 2013 Through Feb. 2017 | 88 |
| Table 28 Number of Investigational New Drug Applications Filed, 2003-2016..... | 89 |
| Table 29 ADCs in Research Pipeline as of Feb. 2017 | 91 |
| Table 30 Orphan Drug Designations Granted for Adcetris | 99 |
| Table 31 Major Alliances for ADC Development..... | 104 |
| Table 32 Abbreviations Used in Antibody Drug Conjugates | 135 |

List of Figures

| | |
|--|----|
| Summary Figure: Global Market for Antibody Drug Conjugates, by Region, 2014-2021 (\$ Millions)..... | 10 |
| Figure 1 Global Market for Antibody Drug Conjugates, by Type of Payload, 2014-2021 (\$ Millions)..... | 38 |
| Figure 2 Global Market for Antibody Drug Conjugates, by Type of mAb, 2014-2021 (\$ Millions)..... | 41 |
| Figure 3 Global Market for Antibody Drug Conjugates, by Type of Linker, 2014-2021 (\$ Millions)..... | 45 |
| Figure 4 Global Market for Antibody Drug Conjugates, by Type of Cancer, 2014-2021 (\$ Millions) | 49 |
| Figure 5 Global Market Shares of Antibody Drug Conjugates, by Type of Cancer, 2016 (%) | 50 |
| Figure 6 Global Market for Breast Cancer Antibody Drug Conjugates, by Region, 2014-2021 (\$ Millions) | 54 |
| Figure 7 Global Market for Lymphoma Antibody Drug Conjugates, by Region, 2014-2021 (\$ Millions) ... | 57 |
| Figure 8 Global Market for Other Types of Antibody Drug Conjugates, by Region, 2014-2021 (\$ Millions) | 60 |
| Figure 9 Global Market Shares of Manufacturers/Suppliers of Antibody Drug Conjugates, 2016 (%) | 64 |
| Figure 10 Global Market for Antibody Drug Conjugates, by Region, 2014-2021 (\$ Millions) | 69 |
| Figure 11 Global Market for CD30 Targeting Antibody Drug Conjugates, by Region, 2014-2021 (\$ Millions) | 74 |
| Figure 12 Global Market for HER2 Targeting Antibody Drug Conjugates, by Region, 2014-2021 (\$ Millions) | 78 |
| Figure 13 Global Market for Other Types of Targeting Antibody Drug Conjugates, by Region, 2014-2021 (\$ Millions) | 81 |
| Figure 14 Number of U.S. Patents on ADCs Issued by Year, 2013 Through Feb. 2017..... | 84 |
| Figure 15 Number of U.S. Patents on ADCs Held by Company, 2013 Through Feb. 2017 | 85 |
| Figure 16 Number of U.S. Patents on ADCs by Assignee's Country, 2013 Through Feb. 2017 | 86 |
| Figure 17 U.S. Patent Shares of ADCs by Assignee's Country, 2013 Through Feb. 2017 (%) | 87 |
| Figure 18 Number of U.S. Patents on ADCs by Type of Assignee, 2013 Through Feb. 2017..... | 88 |



About BCC Research

About BCC Research

With our unparalleled 45-year history, BCC Research provides comprehensive analysis of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

BCC Membership

From market sizing and forecasts, to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. Members benefit from ongoing, unlimited access to the category or collections of their choice, and most membership packages pay for themselves within two to three reports being accessed.

Did you buy this report? You may qualify to apply your purchase price towards a full membership. Call 866-285-7215 or email info@bccresearch.com to request a demo.

BCC Custom Research

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analysis and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: custom@bccresearch.com or 781-205-2429.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 1-62296-521-3
June 2017